Clinical trials: Disease or Disorder
Bipolar Disorder, Anxiety Disorder
Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder
The purpose of this research study is to evaluate the safety, tolerability, and efficacy (how well the drug works) of risperidone compared to placebo (an inactive drug) in the treatment of bipolar disorder with panic disorder or…
- Trial name
- NCT00277654
- Testing
- Risperidone
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Lindner Center of HOPE
Neurogenic Bladder Disorder, Spina Bifida
Complications of Bladder Augmentation in Children
The goal of this observational study is to describe the complications in participants who underwent enterocystoplasty in childhood.
- Conditions
- Neurogenic Bladder Disorder, Spina Bifida, Complications of Surgical Procedures or Medical Care, Child, Only
- Trial name
- AVPED (NCT06733194)
- Where
- France
- Volunteers
- 87 people
- Sponsor
- University Hospital, Clermont-Ferrand
Hepatitis C, Chronic, Hepacivirus
Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED)
In February 2002, a French Consensus Conference on the management of patients with chronic hepatitis C in France was organized. The jury issued several recommendations on pegylated alpha interferon/ribavirin treatment strategy.
- Trial name
- ADEQUATION (NCT00705666)
- Testing
- Peginterferon alfa-2b (SCH 54031), Ribavirin (SCH 18908)
- Volunteers
- 789 people
- Sponsor
- Merck Sharp & Dohme LLC
Hodgkin's Lymphoma
Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)
The purpose of this study is to evaluate the efficacy and safety of combination chemotherapy with etoposide, methylprednisolone, high-dose cytarabine and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's…
- Trial name
- NCT01300156
- Testing
- Oxaliplatin-based chemotherapy (ESHAOx)
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- National Cancer Center, Korea
Chronic Disease, Infectious Disorder
Biospecimen Analysis in Detecting Chemical Concentrations in Patients With Chronic or Infectious Diseases Receiving Meditations
This trial collects and analyzes sweat and saliva samples compared to blood in detecting chemical concentrations in the body in patients with chronic or infectious diseases receiving medications.
- Trial name
- NCT04160429
- Testing
- Biospecimen Collection, Medical Chart Review, Questionnaire Administration
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- City of Hope Medical Center
Liver Cancer, Metastatic Cancer
Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Specialized radiation therapy, such as yttrium Y 90 glass microspheres that deliver a high dose of radiation directly to the…
- Trial name
- NCT00858429
- Testing
- capecitabine, yttrium Y 90 glass microspheres
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Northwestern University
FOXP1, Mental Retardation With Language Impairment and With or Without Autistic Features
FOXP1 Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing FOXP1-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.
FOXP1, also known as Forkhead-box Protein P1, is a transcription factor protein belonging to the FOX gene family. Disruptions in the FOXP1 gene cause a phenotype characterized by global developmental delay, speech deficits, mild…
- Conditions
- FOXP1, Mental Retardation With Language Impairment and With or Without Autistic Features, Autism Spectrum Disorder
- Trial name
- NCT03718923
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Hodgkin Lymphoma
SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma
This is a two-stage, Phase II clinical trial for patients with relapsed or refractory Hodgkin Lymphoma. The purpose of stage I is to evaluate whether treatment with the study drug decitabine in combination with SHR-1210 is safe…
- Trial name
- NCT03250962
- Testing
- SHR-1210, Decitabine
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Chinese PLA General Hospital
AV Block
Left Septal Pacing or Left Bundle Branch Pacing to Avoid Left Ventricle Systolic Dysfunction
Right ventricular apical pacing (RVAP) can produce left ventricular dysfunction (LVD). Conduction system pacing (CSP) has been used successfully to reverse LVD in patients with left bundle branch block.
- Trial name
- STAY II (NCT06707662)
- Testing
- Pacemaker and defibrillator
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Parc de Salut Mar
Gambling Disorder, Substance Use Disorders
Integrative Couple Treatment for Gambling/Substance Use Disorder
The aim of the study is to compare couple-based treatment to individual treatment (treatment as usual) for addiction (gambling or substance use disorder).
- Trial name
- NCT05833503
- Testing
- Integrative Couple Treatment for Addiction (ICT-A), Treatment individual as usually offered
- Where
- 7 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Université du Québec à Trois-Rivières
Tobacco Use Disorder
Varenicline or Nicotine Patch in Promoting Smoking Cessation Among Current Smokers
This pilot clinical trial studies varenicline or nicotine patch in promoting smoking cessation among current smokers. Varenicline or nicotine patch may help people stop smoking
- Trial name
- NCT01771627
- Testing
- varenicline, nicotine patch
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Roswell Park Cancer Institute
Metastatic Solid Tumors
Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer
The purpose of this study is to determine the maximum tolerated dose (MTD) and/or optimal biologic dose(OBD), safety and tolerability, dose-limiting toxicity (DLT) of TAK-117 when administered orally in subjects with advanced…
- Trial name
- NCT01449370
- Testing
- TAK-117
- Where
- 5 sites in United States, Spain and 1 more
- Volunteers
- 125 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
This example study is an open-label, multi-center, adaptive Phase 1/2 trial evaluating the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CAR-NK cell products in adults with relapsed or…
- Conditions
- Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, Extensive-stage SCLC
- Trial name
- NCT07744256
- Testing
- EB-DART-NK01, Lymphodepleting chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
Aorta Disease, Peripheral Artery Disease
Asan Aorta and Peripheral Registry
The purpose of this study is to evaluate the clinical results of patients who received revascularization of the aorta and peripheral artery at Asan Medical Center.
- Trial name
- PTA (NCT06022653)
- Testing
- Treatment
- Where
- South Korea
- Volunteers
- 6,000 people
- Sponsor
- Asan Medical Center
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in participants with recurrent or refractory epithelial…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Recurrent or Refractory Disease After Standard Therapies
- Trial name
- DUAL-OV-CAR-NK (NCT07617753)
- Testing
- Dual-target CAR-NK cell product, Cyclophosphamide, supportive
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Alpha 1-Antitrypsin Deficiency, Emphysema or COPD
PiMZ Longitudinal Cohort (PiMZ Logic)
Alpha-1 Anti-trypsin Deficiency (AATD) is a genetic disease with lung and liver disease presentations. Presentations are variable in the heterozygous population, the most predominant genotype being PiMZ.
- Trial name
- NCT06505603
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- Columbia University
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
NK Cells in Cord Blood Transplantation
This phase I trial studies the side effects and best way to give natural killer cells and donor umbilical cord blood transplant in treating patients with hematological malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission
- Trial name
- NCT01619761
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Breast Cancer
Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression
This is an open-label, single arm, multicenter phase II study evaluating treatment with pembrolizumab in combination with paclitaxel in patients with locally advanced or metastatic non-luminal hormone receptor-positive (HR+)…
- Trial name
- TATEN (NCT04251169)
- Testing
- Pembrolizumab, Paclitaxel
- Where
- 7 sites in Spain
- Volunteers
- 20 people
- Sponsor
- SOLTI Breast Cancer Research Group
All Acutely Ill or Injured Patients
Application of Geographical Information System Data in the Emergency Department, Effect on Trauma Team and Medical Emergency Team Wait
In the Emergency Department Regional Hospital Horsens a monitor will display Geographical Information System data (GIS data) for all ambulances with the hospital as final destination.
- Trial name
- NCT02188966
- Testing
- Geographic Information System
- Where
- Denmark
- Volunteers
- 599 people
- Sponsor
- University of Aarhus
Substance Use Disorder, Mental Illness
Successful Transitions and Reintegration Tools for Veterans (START-VETS)
This study will develop prison reentry materials for Veterans leaving prison.
- Conditions
- Substance Use Disorder, Mental Illness, Recently Incarcerated
- Trial name
- START-VET (NCT04366531)
- Testing
- START-VET, Treatment as usual
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.